These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 20621983)

  • 1. Lack of seroconversion of rheumatoid factor and anti-cyclic citrullinated peptide in patients with early inflammatory arthritis: a systematic literature review.
    Barra L; Pope J; Bessette L; Haraoui B; Bykerk V
    Rheumatology (Oxford); 2011 Feb; 50(2):311-6. PubMed ID: 20621983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The status of rheumatoid factor and anti-cyclic citrullinated peptide antibody are not associated with the effect of anti-TNFα agent treatment in patients with rheumatoid arthritis: a meta-analysis.
    Lv Q; Yin Y; Li X; Shan G; Wu X; Liang D; Li Y; Zhang X
    PLoS One; 2014; 9(2):e89442. PubMed ID: 24586782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rheumatoid Arthritis, Anti-Cyclic Citrullinated Peptide Positivity, and Cardiovascular Disease Risk in the Women's Health Initiative.
    Mackey RH; Kuller LH; Deane KD; Walitt BT; Chang YF; Holers VM; Robinson WH; Tracy RP; Hlatky MA; Eaton CB; Liu S; Freiberg MS; Talabi MB; Schelbert EB; Moreland LW
    Arthritis Rheumatol; 2015 Sep; 67(9):2311-22. PubMed ID: 25988241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody.
    Mikuls TR; O'Dell JR; Stoner JA; Parrish LA; Arend WP; Norris JM; Holers VM
    Arthritis Rheum; 2004 Dec; 50(12):3776-82. PubMed ID: 15593224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
    van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
    Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic utility of anti-cyclic citrullinated peptide antibodies for very early rheumatoid arthritis.
    Matsui T; Shimada K; Ozawa N; Hayakawa H; Hagiwara F; Nakayama H; Sugii S; Ozawa Y; Tohma S
    J Rheumatol; 2006 Dec; 33(12):2390-7. PubMed ID: 16924694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced neutrophil phagocytic capacity in rheumatoid arthritis related to the autoantibodies rheumatoid factor and anti-cyclic citrullinated peptides.
    de Siqueira MB; da Mota LM; Couto SC; Muniz-Junqueira MI
    BMC Musculoskelet Disord; 2015 Jun; 16():159. PubMed ID: 26123215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-cyclic citrullinated peptide antibodies distinguish hepatitis B virus (HBV)-associated arthropathy from concomitant rheumatoid arthritis in patients with chronic HBV infection.
    Lim MK; Sheen DH; Lee YJ; Mun YR; Park M; Shim SC
    J Rheumatol; 2009 Apr; 36(4):712-6. PubMed ID: 19286846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibodies to Cyclic Citrullinated Peptides in Patients With Juvenile Idiopathic Arthritis and Patients With Rheumatoid Arthritis: Shared Expression of the Inherently Autoreactive 9G4 Idiotype.
    Peckham H; Cambridge G; Bourke L; Sen D; Radziszewska A; Leandro M; Ioannou Y
    Arthritis Rheumatol; 2017 Jul; 69(7):1387-1395. PubMed ID: 28380667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis.
    Chen HA; Lin KC; Chen CH; Liao HT; Wang HP; Chang HN; Tsai CY; Chou CT
    Ann Rheum Dis; 2006 Jan; 65(1):35-9. PubMed ID: 15975966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic performance of anti-cyclic citrullinated peptide and rheumatoid factor in patients with rheumatoid arthritis.
    Chang PY; Yang CT; Cheng CH; Yu KH
    Int J Rheum Dis; 2016 Sep; 19(9):880-6. PubMed ID: 25940989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Only rheumatoid factor-positive subset of anti-citrullinated peptide/protein antibody-negative rheumatoid arthritis may seroconvert to anti-citrullinated peptide/protein antibody-positive.
    Hiwa R; Ohmura K; Nakabo S; Terao C; Murakami K; Nakashima R; Imura Y; Yukawa N; Yoshifuji H; Hashimoto M; Furu M; Ito H; Fujii T; Mimori T
    Int J Rheum Dis; 2017 Jun; 20(6):731-736. PubMed ID: 28198158
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide.
    Schellekens GA; Visser H; de Jong BA; van den Hoogen FH; Hazes JM; Breedveld FC; van Venrooij WJ
    Arthritis Rheum; 2000 Jan; 43(1):155-63. PubMed ID: 10643712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis.
    De Rycke L; Verhelst X; Kruithof E; Van den Bosch F; Hoffman IE; Veys EM; De Keyser F
    Ann Rheum Dis; 2005 Feb; 64(2):299-302. PubMed ID: 15166003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis.
    Quartuccio L; Fabris M; Salvin S; Atzeni F; Saracco M; Benucci M; Cimmino M; Morassi P; Masolini P; Pellerito R; Cutolo M; Puttini PS; De Vita S
    Rheumatology (Oxford); 2009 Dec; 48(12):1557-9. PubMed ID: 19789202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The role of anti-cyclic citrullinated peptide (anti-CCP) antibodies in serologic diagnosis and evaluation of disease activity in rheumatoid arthritis].
    Aridoğan BC; Kaya S; Savaş S; Cetin ES; Akkuş S; Demirci M
    Mikrobiyol Bul; 2008 Oct; 42(4):669-74. PubMed ID: 19149089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment.
    Caramaschi P; Biasi D; Tonolli E; Pieropan S; Martinelli N; Carletto A; Volpe A; Bambara LM
    Rheumatol Int; 2005 Nov; 26(1):58-62. PubMed ID: 15726373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparison and relevance of rheumatoid factors, antikeratin antibodies and anti-cyclic citrullinated peptides antibodies in rheumatoid arthritis].
    Galati S; Beauvillain C; Renier G; Jeannin P; Masson C; Chevailler A
    Ann Biol Clin (Paris); 2008; 66(2):157-64. PubMed ID: 18390426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autoantibodies in rheumatoid arthritis: association with severity of disease in established RA.
    Agrawal S; Misra R; Aggarwal A
    Clin Rheumatol; 2007 Feb; 26(2):201-4. PubMed ID: 16572283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of treatment with infliximab on anticyclic citrullinated peptide antibody and rheumatoid factor in patients with rheumatoid arthritis.
    Ahmed MM; Mubashir E; Wolf RE; Hayat S; Hall V; Shi R; Berney SM
    South Med J; 2006 Nov; 99(11):1209-15. PubMed ID: 17195414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.